Healthcare ❯ Pharmaceuticals

Diabetes Treatment

GLP-1 Drugs GLP-1 Agonists Obesity Management Weight Management Mounjaro Semaglutide GLP-1 Receptor Agonists Type 2 Diabetes Medications Weight Loss Obesity Treatment Insulin Therapy Clinical Trials Weight-loss Drug Januvia Injectable Drugs Ozempic Novo Nordisk Sales Performance Drug Pricing Medication GLP-1 Medications Medication Misuse New Medications Metformin Weight Loss Injections Market Competition GLP-1 RA Medications GLP-1 Therapies Injectable Medications Weight Loss Drugs

Lilly Posts Blowout Quarter as Global GLP‑1 Push Tests Price‑for‑Volume Strategy

Expanded payer coverage, oral Foundayo filings and positive retatrutide trials put pressure on international launches to convert higher patient volume into sustained revenue.

Lilly and Resilience Announce $750 Million Ohio Expansion for KwikPen and Injectables

Large Observational Studies Link GLP‑1 Drugs to Lower Cancer Rates and Slower Progression

Novo Nordisk Lifts 2026 Outlook as Wegovy Pill Powers Big Q1 Beat

Studies Link GLP-1 Drugs to Lower Addiction and Overdose Risks

Insulet Beats Q3 Targets and Lifts 2025 Outlook on Surging Omnipod Sales

Metformin Linked to Lower Dementia and Mortality Risks in Overweight, Obese Adults